Novo Nordisk


Zuellig Pharma
Concise Prescribing Info
Adults, adolescents & childn ≥10 yr w/ type 2 DM in combination w/ oral glucose-lowering drugs &/or insulin together w/ diet & exercise to provide sufficient glycaemic control. Reduce risk of major adverse CV events (MACE) eg, CV death, non-fatal MI & stroke in adults w/ type 2 diabetes who have established or at high risk for CV disease.
Dosage/Direction for Use
SC Initially 0.6 mg daily, may be increased to 1.2 mg after at least 1 wk. Max: 1.8 mg daily.
May be taken with or without food: Preferably administered at the same time each day.
Special Precautions
Not to be inj IV or IM. Not to be used in type 1 DM or diabetic ketoacidosis. Not an insulin substitute. Discontinue use if pancreatitis is suspected. Not recommended in CHF NYHA class IV, inflammatory bowel disease; diabetic gastroparesis. Preexisting thyroid disease; hypoglycaemia. Ensure adequate fluid intake. May affect ability to drive & use machines. Not recommended in end-stage renal disease or severe hepatic impairment. Not to be used during pregnancy & lactation. Childn & adolescents <10 yr.
Adverse Reactions
Nausea, diarrhoea. Nasopharyngitis, bronchitis; hypoglycaemia, anorexia, decreased appetite; headache, dizziness; increased heart rate; vomiting, dyspepsia, upper abdominal pain, constipation, gastritis, flatulence, abdominal distension & discomfort, GERD, toothache; rash; fatigue, inj site reactions; increased lipase & amylase.
Drug Interactions
Frequent monitoring of INR w/ warfarin & other coumarin derivatives.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BJ02 - liraglutide ; Belongs to the class of glucagon-like peptide-1 (GLP-1) analogues. Used in the treatment of diabetes.
Victoza soln for inj 6 mg/mL
3 mL x 2 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in